News - Serada

Filter

Current filters:

Serada

Popular Filters

Depomed shares plummet as Ph III Serada trial fails one endpoint

17-10-2011

Shares of US specialty drugmaker Depomed (Nasdaq: DEPO) fell 28.2% to $4.52 last Friday, after the company…

DepomedgabapentinNeurologicalPharmaceuticalResearchSerada

Back to top